In Brief
Exposure to unmethylated CpG DNA (CpG) from bacteria is associated with a reduced risk of developing asthma. Sabatel et al. find that CpG exposure leads to higher numbers of lung interstitial macrophages that prevent allergic inflammation through the production of the regulatory cytokine interleukin-10.
INTRODUCTION
The increased prevalence of allergic asthma over the past few decades points to alterations in the environment (Eder et al., 2006) . The hygiene hypothesis postulates that decreased exposure to environmental and commensal microbes or their products, partly because of changes associated with urban lifestyles, is responsible for this rise (Strachan, 1989; von Mutius, 2016) . In line with this hypothesis, epidemiological studies associate growing up on a farm, where exposure to bacterial endotoxin (lipopolysaccharide [LPS] ) is high, with reduced risk of allergic sensitization (Braun-Fahrl€ ander et al., 2002; von Mutius, 2016) . However, whether LPS mediates the aforementioned protective effects is uncertain. Indeed, concurrent studies in non-rural environments have suggested that exposure to LPS is instead a risk factor for increased asthma prevalence and severity (Thorne et al., 2005) . Moreover, although LPS has demonstrated protective effects in some animal models (Schuijs et al., 2015) , it has also been shown to promote experimental asthma (Eisenbarth et al., 2002; Hammad et al., 2009) .
Another candidate for mediating the protective effects of microbe-rich environments is bacterial DNA, which contains unmethylated CpG motifs with immunomodulatory properties (Krieg, 2006) . Bacterial DNA, like LPS, is present in high amounts in dust from rural homes (Roy et al., 2003) , and treatment with synthetic CpG DNA (CpG) consistently prevents allergic sensitization in animal models (Kline et al., 1998; Sur et al., 1999) . Moreover, CpG is able to reverse established asthma in animals (Broide et al., 1998; Kline et al., 2002) and has shown efficacy in attenuating allergic disorders in human clinical trials (Beeh et al., 2013; Creticos et al., 2006; Krieg, 2006) . How CpG exerts these immunomodulatory effects remains unclear. It was initially proposed that CpG, which is often co-administered with allergens, redirects allergen-specific T helper 2 (Th2) cell responses toward Th1 or regulatory T cell responses (Broide et al., 1998; Kline et al., 2002; Kline et al., 1998; Krieg, 2012 CpG is capable of conferring protection in the absence of allergens (Beeh et al., 2013; Broide et al., 1998; Krieg, 2012) , suggesting that it acts independently of the adaptive immune system. In 2009, we identified a small population of regulatory macrophages in the lung interstitium of mice (Bedoret et al., 2009 ). These lung interstitial macrophages (IMs), also found in humans (Hoppst€ adter et al., 2010) , spontaneously produce the immunosuppressive cytokine interleukin-10 (IL-10), a hallmark of regulatory macrophages (Mosser and Edwards, 2008) . Moreover, when exposed to low doses of LPS, IMs, which are located in the vicinity of lung dendritic cells (DCs), can counteract the capacity of LPS-activated DCs to induce Th2 responses against harmless antigens (Bedoret et al., 2009 ). In agreement with this, mice lacking functional IMs, but not wild-type (WT) mice, develop overt asthmatic reactions when exposed to low doses of a mixture of allergen and LPS (Bedoret et al., 2009 ). However, the immunosuppressive effects of IMs are overwhelmed when the airways are exposed to high levels of allergens and LPS, given that 100% of WT mice develop asthma upon exposure to high doses of house dust mite (HDM) extracts, a phenomenon that requires Toll-like receptor 4 (TLR4) activation by HDM-borne LPS (Hammad et al., 2009 ). We therefore reasoned that pathogen-associated molecular patterns (PAMPs) other than LPS could improve the immunosuppressive effects of IMs and thereby explain how a microbe-rich environment reduces the risk of asthma development.
Here, we found that CpG is able to robustly expand the IM population. CpG-induced IMs (CpG IMs) developed from local and splenic reservoir monocytes and were able, by producing IL-10, to confer protection against allergic inflammation even when mice were sensitized and challenged with high doses of HDM. Our findings reveal a role for regulatory IMs shed in the protective effect of CpG exposure in allergic airway inflammation and suggest that similar mechanisms might underlie the reduced risk of human asthma development that is associated with exposure to a microbe-rich environment.
RESULTS

A Simplified Flow Cytometry Strategy Discriminates Lung Monocyte and Macrophage Subsets in Mice
In order to identify the monocyte and macrophage populations associated with the lung at steady state, we set up a simplified six-step, five-color flow cytometry staining procedure on mononuclear-cell-enriched lung cells isolated from whole, non-lavaged, perfused lungs of naive C57BL/6 WT mice. To encompass all monocyte and macrophage populations, we gated sequentially on living singlet cells (step 1), CD45 + immune cells (step 2), and cells positive for the pan-monocyte and -macrophage marker F4/80 (step 3) ( Figure 1A ). Alveolar macrophages (AMs), the most abundant lung phagocytic cells present in the airways ( Figure S1A) Figure 1B-1D ), a transcription factor controlling differentiation and survival of patrolling monocytes (Hanna et al., 2011) , demonstrating that these cells were patrolling monocytes. Finally, Ly-6C lo CD64 hi cells were identified as IMs. Indeed, these cells were absent in the broncho-alveolar lavage fluid (BALF) ( Figure S1A ) and were positive for MHC-II and the macrophage markers Mertk and CD169 ( Figure 1C ). IMs were already present after birth ( Figure S1B ), expressed low levels of CCR2, and were found in similar numbers in 6-to 10-week-old Ccr2
, and WT mice ( Figure 1D ). However, their numbers were significantly lower in 1-year-old Ccr2 À/À mice than in age-matched controls ( Figure S1C ), suggesting that IMs represent a heterogeneous population and are partially maintained by classical monocytes in adults, as reported by others (Tan and Krasnow, 2016 Data in (A)-(C) and (I) represent one of at least six mice from at least three independent experiments. Data in (D) and (H) show the mean + SEM pooled from three independent experiments (n = 6-10 per group). Data in (E) and (F) show the mean + SEM from one of three independent experiments (n = 3-4 per group). p values were calculated with a one-way (D-F) or two-way (H) ANOVA followed by Tukey's post hoc tests (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). Scale bars, 10 mm. See also Figure S1 for additional information regarding the phenotype, localization, and IL-10 production by lung monocytes and macrophages. (Hashimoto et al., 2013) . However, 35% of the IM pool was constituted by WT partner cells after 6 months of parabiosis, strongly supporting that IMs are, at least in part, replenished by circulating blood monocytes in adults, a feature shared with gut macrophages (Bain et al., 2014) . IMs constitutively expressed IL-10, as quantified in vivo by the use of IL-10-b-lactamase reporter ITIB mice (Bouabe et al., 2011) and ex vivo by ELISA (Figures 1E and 1F ; Figure S1E ). Notably, a spontaneous IM-derived IL-10 production was dependent on the adaptor molecule MYD88 but independent of TLR9 ( Figure S1F ), concordant with the fact that LPS, which mediates signaling through MYD88, sustains IM-derived IL-10 at steady state (Bedoret et al., 2009) . Upon CpG or LPS stimulation, the increased ability of IMs to produce IL-10 relied on TLR9 and MyD88 or only MyD88, respectively ( Figure S1F ).
When applied to the lungs during HDM-induced airway allergy, the flow cytometry strategy identified similar cell populations ( Figure S1G ).
To determine which cells were truly located in the lung tissue, we depleted blood-vessel-associated monocytes and macrophages by injecting clodronate-containing liposomes (Clo-Lips) intravenously 24 hr before analysis ( Figure 1G ). This regimen had no effect on AMs or IMs but efficiently depleted patrolling monocytes and a substantial part (z60%) of Ly-6C hi monocytes ( Figure 1H ), showing that most monocytes, except some Ly-6C hi monocytes, were associated with the lung vasculature. Concordant with this, combined in vivo and ex vivo anti-CD45 stainings confirmed that AMs, IMs, and only a fraction of Ly-6C hi monocytes were truly located in the lungs of WT mice (Figures S1H and S1I). Anti-Ly-6C immunostaining of lung sections from Clo-Lip-treated WT and Ccr2 À/À mice confirmed that the Ly-6C + cells were located in the lung parenchyma ( Figure 1I ). Notably, in Ccr2 À/À mice, Clo-Lip injection did not affect the amount of Ly-6C hi monocytes, whose numbers and localization were similar to those from Clo-Lip-treated WT mice (Figures 1H and 1I) , indicating that these monocytes established in the lung independently of CCR2. In the following sections, we refer to these CCR2-independent, lung-infiltrating monocytes, which were already present at the age of 3 days ( Figure S1J ), as lung monocytes. To assess whether lung monocytes represented a monocyte population distinct from classical CCR2-dependent blood monocytes, we performed a transcriptomic comparison of Ly-6C hi monocytes recovered from perfused lung of WT mice (z60% of CCR2-dependent classical blood monocytes and z40% of lung monocytes) and Ccr2 À/À mice (more than 95% of lung monocytes). This analysis revealed only one differentially expressed gene, namely Ccr2 (Figures S1K and S1L), showing that lung monocytes fully corresponded to classical Ly-6C hi monocytes.
CpG Induces TLR9-Dependent IM Expansion
We hypothesized that exposure to certain PAMPs, such as LPS or CpG, might protect against asthma by enhancing the immunosuppressive potential of IMs. First, we confirmed expression of most TLRs on IMs ( Figure S2A ) and assessed how local exposure to PAMPs, especially TLR ligands, or a local infection would quantitatively affect IMs ( Figure 2A ; Figure S2B ). Although several PAMPs, including LPS, were able to significantly expand IMs, CpG was by far the most potent in increasing IM numbers 1 week after a single intranasal (i.n.) exposure (42.5-fold with an average of 1.7 3 10 6 cells) ( Figure 2B ; Figure S2C ), a phenomenon that was dependent on signaling through TLR9 ( Figure 2C ). Such expansion persisted up to 8 weeks after treatment, was also observed to a lesser extent when CpG was administered by a systemic route, and was associated with the presence of a small fraction of CpG IMs into the BALF ( Figures S2D-S2G ).
Conversely, pulmonary infection with Influenza A virus (PR8) or
Streptococcus pneumoniae did not have any significant effect on IM numbers 7 days after infection ( Figure 2B ). Of note, AM counts remained unchanged after CpG treatment and were moderately increased after LPS treatment (Figures S2H and S2I) .
We compared gene expression profiles between CpG IMs and steady-state IMs (SS IMs). Principal-component analysis (PCA) revealed that CpG IMs clustered more closely with SS IMs than with AMs ( Figure 2D ), but 285 genes were differentially regulated between CpG IMs and SS IMs (fold change > 2, p < 0.01). Among genes upregulated in CpG IMs, gene-set enrichment analysis (GSEA) revealed a significant enrichment of genes implicated in macrophage activation and differentiation, such as targets of c-MYC (Aziz et al., 2009) or genes upregulated by activation of mTORC1 or NOTCH signaling (Covarrubias et al., 2016; Monsalve et al., 2009) (Figure 2E ).
Protein expression of several surface markers was comparable between CpG IMs and SS IMs, except for CD11b and CD115, which were upregulated in CpG IMs, and for CD62L, SiglecF, and CD169, which were downregulated ( Figure S2J ).
Functionally, in comparison with SS IMs, CpG IMs exhibited a hypersuppressive profile. Indeed, the percentage of IL-10 + cells within CpG IMs was increased, leading to a 55-fold increase in the numbers of IL-10-producing IMs upon CpG treatment (Figures 2F and 2G) . Furthermore, the level of IL-10 expression within CpG IMs was substantially greater than that in SS IMs ( Figures 2F and 2G ), leading to a global 550-fold increase in 
CpG-Induced IMs Prevent Allergic Sensitization to Inhaled Allergens
We wondered whether the hypersuppressive profile of CpG IMs might contribute to the protective effects of CpG on asthmatic sensitization. First, we developed a mouse model of asthma prevention by CpG, during which WT mice were intranasally exposed to CpG 7 days before two weekly i.n. instillations of 100 mg HDM ( Figure 3A ). This regimen of HDM exposure bypassed the regulatory functions of SS IMs, given that 100% of HDM-exposed WT mice developed airway hyperreactivity (AHR), BALF eosinophilia, HDM-specific lymph node (LN) Th2 responses, peribronchial inflammation, and increased mucus production, as well as increased activation of lung DCs and enhanced DC migration to the LNs (Figures 3B-3G Figure 3J ). AHR, eosinophilia, HDM-specific Th2 responses, lung inflammation, and mucus production were significantly reduced when CpG IMs sorted from lungs of CpG-treated WT mice were transferred before HDM exposures (Figures 3K-3N ; Figures S3C and S3D ). Such protection was specific to CpG IMs and relied on CpG-IM-derived IL-10, given that transfer of WT AMs or Il10 À/À CpG IMs failed to improve the characteristic features of asthma (Figures 3J-3N ; Figures S3C and S3D ). These results demonstrate that IL-10-producing IMs were essential for the protective effects of CpG against sensitization to inhaled allergens.
CpG-Induced IMs Mediate the Immunotherapeutic Effects of CpG on Established Asthma
CpG has already proven its efficacy in attenuating established asthma in animal models and in human clinical trials. Here, we developed a model of immunotherapy based on CpG treatment of HDM-sensitized WT mice before HDM challenge ( Figure 4A) .
CpG was more potent in expanding IL-10-producing CpG IMs and in decreasing AHR, eosinophilic inflammation, HDM-specific Th2 responses, mucus production, and DC activation than in sham-treated asthmatic counterparts, features that were not observed in Tlr9 À/À mice (Figures 4B-4I ; Figures S4A and   S4B ). Moreover, CpG IMs were sufficient to confer protection, given that adoptive transfer of CpG IMs before HDM challenge markedly decreased airway allergy in HDM-sensitized mice, an effect that was not observed when WT AMs or Il10 À/À CpG IMs were transferred (Figures 4J-4N ; Figures S4C and S4D) . Importantly, the expansion of IL-10-producing IMs and the immunotherapeutic effects of CpG persisted up to 8 weeks after CpG treatment ( Figures S4E-S4L) . Moreover, similar CpG-induced IM-mediated protection was observed in an asthma model based on systemic sensitization with ovalbumin and alum ( Figures S4M-S4Q ).
CpG Expands IMs Mainly from CCR2-Independent Monocytes
Given the crucial contribution of CpG IMs to asthma prevention and treatment in our models, we sought to determine the origin of these macrophages. In adult tissues, macrophages are maintained or expanded by local proliferation or differentiation from CCR2-dependent BM-derived classical monocytes (Ginhoux and Guilliams, 2016) . First, to assess the proliferative ability of IMs, we analyzed the incorporation of EdU by IMs after CpG treatment. CpG exposure did not increase the percentage of EdU + IMs at the time points analyzed, providing no support for local proliferation of IMs after CpG treatment ( Figure 5A ). Second, we quantified the numbers of CpG IMs in Ccr2 À/À mice. Surprisingly, CpG IM numbers were only slightly decreased in Ccr2 À/À mice ( Figure 5B ), whereas LPS IM numbers were robustly reduced ( Figure S5A ), supporting the idea that CpG IMs, unlike LPS IMs, developed mostly from monocytes that were recruited independently of the BM. (legend continued on next page) cells to the level of that observed in blood B lymphocytes, namely 100% of CCR2 independence when mice were analyzed at 12 weeks of age ( Figures 5D-5F ). These results demonstrate that CpG IMs mainly arose from CCR2-independent precursors. Notably, when chimeric mice were exposed to LPS, IM chimerism was not substantially affected and was similar to that of blood Ly-6C hi monocytes, demonstrating that LPS IMs arose from BM-derived classical monocytes ( Figures S5D  and S5E ). All together, these results support that CpG IMs neither expanded through local proliferation nor substantially differentiated from CCR2-dependent BM-derived classical monocytes but instead mainly originated from CCR2-independent cells.
Lung and Splenic Monocytes Are the Precursors of CpG IMs
Earlier in this article, we defined lung monocytes as CCR2-independent classical monocytes infiltrating the lung parenchyma ( Figure 6A ). Given that IM expansion upon CpG sensing was mainly independent of CCR2, we hypothesized that lung monocytes could act as a local reservoir for CpG IMs.
First, we validated the CCR2 independence of lung monocytes by conducting parabiosis and mixed-BM-chimera experiments. CD45.1 + WT and CD45.2 + Ccr2 À/À mice exchanged their circulation for 6 months, and the enrichment of WT and Ccr2
partner cells within the Ccr2 À/À and WT hosts, respectively, was analyzed 24 hr after intravenous (i.v.) Clo-Lip treatment (Figure 6B) . Notably, for lung monocytes, a comparable enrichment of partner cells was observed in WT and Ccr2 À/À hosts ( Figure 6B ), indicating that these cells were continually replenished by circulating cells independently of CCR2. In BM-reconstituted competitive chimeras, lung monocytes were also repopulated with CCR2-independent engrafted cells, consistent with our findings in parabiotic mice (Figures 6C-6E ; Figures  S6A and S6B ). Our data so far are consistent with the idea that a precursorproduct relationship could exist between lung monocytes and CpG IMs. When we analyzed the kinetics of the appearance of CpG IMs in vivo, we observed a differentiation pattern from Ly-6C hi CD64
lo to Ly-6C lo CD64 hi cells in both WT and Ccr2 À/À mice ( Figure 6F ). With the progressive acquisition of CD64 and the subsequent loss of Ly-6C, the Ly-6C/CD64 plot looked like a waterfall (arrows in Figure 6F ), suggesting that lung monocytes might give rise to CpG IMs. Next, we tested whether lung monocytes could respond to CpG and differentiate into IM-like cells ex vivo. Lung monocytes sorted via fluorescence-activated cell sorting (FACS) expressed higher levels of Tlr9 than did AMs or IMs ( Figure 6G ) and were able to respond to CpG, as shown by increased phosphorylation of Erk kinase (H€ acker et al., 1999) ( Figure 6H ). Ex vivo CpG treatment of lung monocytes promoted their survival and triggered the same waterfall over time as in vivo treatment did ( Figures  6I and 6J ), a phenomenon that was dependent on TLR9 (Figure S6C ). Of note, this waterfall was not observed in LPS-stimulated lung monocytes ( Figure S6D ). Our data thus support that lung monocytes can differentiate into CpG IMs. Nevertheless, the quantity of lung Ly-6C hi cells and CpG IMs 1 and 7 days after CpG treatment, respectively ( Figures 6K and 5B) , largely exceeded the number of lung monocytes present at steady state ( Figure 1H ). We thus tested whether such lung monocytes were able to proliferate in situ, but no increase in EdU incorporation was detected 1 day after CpG treatment ( Figure 6L ; Figure S6E) , when their numbers were >10-fold higher than on day 0 in both WT and Ccr2 À/À mice ( Figure 6K ). Of note, after LPS treatment, this increased number of Ly-6C hi cells was seen only in WT mice and not in Ccr2 À/À mice, adding further support to the BM origin of LPS IMs ( Figure S6F ). These results suggest that, specifically upon CpG stimulation, additional CCR2-independent monocytes were recruited from a distal reservoir and differentiated into CpG IMs. Interestingly, the spleen has been shown to constitute a reservoir of CCR2-independent monocytes, which were already present in 3-day-old mice ( Figure S7A ) and which can migrate to inflammatory tissues in an angiotensin II type 1 (AT-1)-receptor-dependent manner (Swirski et al., 2009 ). Splenic monocytes expressed higher levels of Tlr9 than did AMs ( Figure 7A) , and, like for lung monocytes, ex vivo CpG stimulation promoted their survival and differentiation into CpG-IM-like cells ( Figure 7B) , showing that they can respond to CpG. Notably, 1 day after i.n. CpG treatment, splenic monocyte numbers were significantly decreased, which was associated with an increase in Ly-6C hi monocytes in the lungs of both WT mice and mice lacking AT-1 receptor (Agtr1a À/À ) ( Figures 7C and 7D ). To assess the exact contribution of splenic monocytes to the pool of lung monocytes and CpG IMs, we quantified their numbers 1 and 7 days after CpG treatment, respectively, in splenectomized Ccr2 À/À mice. As shown in Figures 7E and 7F , the pools of lung monocytes and CpG IMs were significantly reduced when the spleen was absent. SS IM numbers were unaffected by splenectomy ( Figure 7F ). Thus, the spleen constitutes a reservoir of monocytes that can seed the lung independently of angiotensin signaling and differentiate into CpG IMs. Of note, when injected subcutaneously in Ccr2 À/À mice, CpG induced recruitment of monocytes not only in the lung but also in other organs such as the heart and liver. However, except in the lung, this was not associated with an increase in macrophage numbers 7 days later. Conversely, i.n. CpG injection in Ccr2
mice promoted the recruitment of monocytes in the lung, but not in the heart or liver ( Figures 7G and 7H ). All together, these data suggest that CpG could mobilize CCR2-independent monocytes but that additional lung-specific signals directed their seeding into the lung and their differentiation into regulatory IMs.
(J-N) Experimental outline (J), dynamic airway resistance upon methacholine inhalation (K) , BALF eosinophil counts (L), cytokine concentrations in culture supernatants of BLN cells restimulated with HDM (M), and H&E staining of lung sections (N). Data show the mean + SEM (B and K) or mean + SEM and are pooled from at least three independent experiments (n = 6-16 per group) (C-F, H, I, L, and M) or represent one of two independent experiments (n = 4 per group) (H and I). p values were calculated with one-way ANOVA followed by Tukey's post hoc tests (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). Data in (G) and (N) represent one of at least six mice from at least two independent experiments. Scale bars, 32 mm. See also Figure S4 for PAS stainings, the long-term therapeutic model, and the assessment of the protective effects of CpG IMs in an ovalbumin and alum model. 
(legend continued on next page)
In an attempt to identify the chemokines involved in splenic monocyte recruitment, we performed a chemokine array on lung extracts and found that CpG instillation induced increased levels of several chemokines, an effect that was, however, also observed with LPS ( Figures 7I and 7J) . Among those chemokines, CCL2 (MCP-1), CCL5 (RANTES), and CCL9 (MIP-1g) were not only the most prominent ones but also the ones whose receptors (i.e., CCR2, CCR5, and CCR1, respectively) were the most expressed in Ly-6C hi monocytes (Figures 7I-7K ). To assess the potential role of these chemokines, we used neutralizing antibodies in vivo. Individual or combined inhibition of CCL2, CCL5, and CCL9, however, did not influence the numbers of lung monocytes in Ccr2 À/À mice 1 day after CpG treatment ( Figures S7B-S7D ), suggesting that splenic monocytes were attracted to the lung independently of those signals.
DISCUSSION
We have shown that IMs substantially expanded in response to CpG, which, unlike LPS, has demonstrated consistent antiallergic effects in humans and animals (Beeh et al., 2013; Broide et al., 1998; Creticos et al., 2006; Krieg, 2006; Sur et al., 1999) . Not only were CpG IMs 42 times more numerous than SS IMs, but their overall IL-10 production was also increased 550-fold. This increased regulatory capacity of CpG IMs was associated with protection against asthma sensitization and exacerbation in experimental models in which the suppressive activity of SS IMs was overcome. Using WT mice adoptively transferred with WT or Il10 À/À CpG IMs and Tlr9 À/À mice, in which CpG-mediated IM expansion was abolished, we further demonstrated that CpG IMs were not only necessary but also sufficient for mediating the protective effects of CpG through the production of IL-10. Finally, we showed that the number of CpG IMs remained elevated for at least 8 weeks after CpG administration, which, in addition to the fact that CpG has been reported to induce sustained epigenetic modifications in macrophages (Ostuni et al., 2013) , could account for the long-lasting innate effects of CpG. Given that SS IMs exert their suppressive activity by inhibiting maturation and migration of lung DCs (Bedoret et al., 2009) , which are essential for both development and restimulation of Th2 cells (Lambrecht et al., 2000; van Rijt et al., 2005) , and that DC activation was dampened in CpG-treated HDM-challenged mice, we speculate that CpG durably reinforces the ability of IMs to control DC function and, therefore, to break the link between innate and adaptive immunity. This study thus provides a possible mechanism, i.e., induction of hypersuppressive IMs, by which CpG exerts its immunotherapeutic effects in animals and humans and by which exposure to the environmental microbiome, especially to farm dust, which is known to be rich in bacterial DNA (Roy et al., 2003) , protects from asthma (Braun-Fahrl€ ander et al., 2002; von Mutius, 2016) . The ''mononuclear phagocyte system'' model, proposed in 1968 by van Furth and collaborators (van Furth and Cohn, 1968) , postulates that tissue-resident macrophages are maintained from a constant supply of blood monocytes that extravasate into tissues. However, this model has been challenged by recent studies demonstrating that, under normal conditions, most macrophages arise from embryonic progenitors and selfrenew in tissues throughout adulthood (Ginhoux and Guilliams, 2016; Gomez Perdiguero et al., 2015) . The only exceptions are gut, dermis, and heart macrophages that, in accordance with the model of van Furth, rely on the constant recruitment of CCR2-dependent classical monocytes to maintain their population (Bain et al., 2014; Epelman et al., 2014; Tamoutounour et al., 2013) . Our data from parabiotic mice support that IMs are also, at least in part, maintained by circulating monocytes in adults, as reported recently (Tan and Krasnow, 2016) . During inflammation, macrophages expand through the same mechanisms, namely local proliferation and differentiation from recruited CCR2-dependent BM-derived classical monocytes (Davies et al., 2013) . Our results from experiments in Ccr2
, clodronate-treated, chimeric, parabiotic, and splenectomized mice are consistent with an unexpected model in which most CpG IMs can expand from CCR2-independent lung and splenic reservoir monocytes after CpG stimulation. In this model, CpG exerts multiple functions. First, it promotes the mobilization of splenic reservoir monocytes to the lung independently of MCP-1, RANTES, and MIP-1g. Second, it triggers differentiation of not only these recruited monocytes but also the herein identified CCR2-independent, lung-infiltrating monocytes into IMs with a hypersuppressive profile.
Noteworthy, CpG and LPS appeared to have distinct effects on the recruitment of monocytes to the lung and their differentiation into suppressive IMs. First, CpG induced a substantial mobilization of monocytes from the spleen (i.e., a CCR2-independent reservoir), whereas LPS mainly triggered mobilization from the BM (i.e., a CCR2-dependent reservoir). Second, CpG acted directly on monocytes in vitro to promote their differentiation into macrophages, whereas LPS did not. Third, CpG exposure was able to strikingly increase IM ability to produce IL-10, which was not the case for LPS. Because CpG and LPS are known to act via distinct TLRs, which are expressed at different levels on different structural and immune cells, CpG and LPS most likely induce distinct biological responses in the spleen, BM, lungs, and monocytes themselves, creating a specific microenvironment tailoring IM origin, differentiation, and function.
Given that the numbers of lung reservoir monocytes were identical in WT and Ccr2 À/À mice, it was tempting to speculate that these cells were different from classical monocytes. However, both cell types had indistinguishable transcriptomes, attesting that lung reservoir monocytes are actually classical monocytes. Although classical monocytes are thought to depend on CCR2 to leave the BM, our results indicate that a fraction of classical monocytes might exit the BM in a CCR2-independent manner to seed the pulmonary and splenic monocyte (E and F) The percentages of chimerism and of CCR2 independence of blood B lymphocytes, neutrophils (i.e., 50% chimerism and 100% CCR2 independence), and monocytes (i.e., z10% chimerism and z20% CCR2 independence) were used as controls. Data in (B) and (E) show the mean + SEM and are pooled from three independent experiments (n = 12-15 per group). p values were calculated with a two-way (B) or one-way (E) ANOVA followed by Tukey's post hoc tests (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). D, day. See also Figure S5 for the CCR2 dependence of LPS IMs and numbers of AMs, SS IMs, LPS IMs, and CpG IMs before irradiation and after BM reconstitution. reservoirs. Identifying the network of chemokine(s) and chemokine receptor(s) orchestrating the traffic of these cells will require additional work.
It has been suggested that the anti-allergic properties of CpG were mediated by plasmacytoid DCs (pDCs), which are known to not only express TLR9 but also play a key role in preventing experimental asthma (de Heer et al., 2004; Krieg, 2006) . However, lung pDCs, unlike the other pDC subsets, lack TLR9 expression and therefore cannot account for the role of CpG in regulating lung immune responses (Chen et al., 2006) . We have shown here that lung and splenic reservoir monocytes expressed TLR9, which was required for differentiation of CCR2-independent monocytes into IMs after CpG stimulation. Our study thus identifies those reservoir monocytes as the TLR9-expressing cells mediating the immunomodulatory effects of CpG in the lung. Of note, it has been demonstrated that human IMs express TLR9 and are able to increase their production of IL-10 upon bacterial DNA stimulation (Hoppst€ adter et al., 2010) , suggesting that our findings in mice are relevant to humans. Moreover, polymorphisms in the TLR9 promoter region have been associated with an increased risk of asthma development (Lazarus et al., 2003; Smit et al., 2009) , supporting the idea that environmental CpG exerts a protective role in humans and that loss of functional TLR9 in human IMs might contribute to asthma development.
In conclusion, our study shows that lung and splenic reservoir monocytes use TLR9 to specifically sense bacterial CpG and massively differentiate into IMs endowed with enhanced antiallergic properties. These findings are of pathophysiological importance because they provide a possible mechanistic explanation for the hygiene hypothesis and for the protective effects of synthetic CpG in experimental models and human clinical trials. Moreover, they reinforce the idea that therapeutic strategies aimed at ameliorating the inhibitory properties of IMs could help control asthma.
EXPERIMENTAL PROCEDURES
A full description of the experimental procedures can be found in the Supplemental Information.
, and Agtr1a À/À C57BL/6 mice were from the Jackson Laboratory. Tlr9 À/À and IL-10-b-lactamase reporter (ITIB) mice were generated by others (see Supplemental Information). All mice were used at 6-10 weeks of age unless otherwise indicated. All experimental procedures and protocols were approved by the local ethics committee. Additional information can be found in the Supplemental Information.
Reagents and Antibodies
Mouse non-CpG DNA (ODN, 5 0 -GCTTGATGACTCAGCCGGAA-3 0 ; reference no. HC4034) and CpG DNA (5 0 -TCCATGACGTTCCTGATGCT-3 0 ; reference no. HC4033) were from Sanbio. HDM extracts (HDM from Dermatophagoides farinae) were from Greer Laboratories. Additional reagents and antibodies are described in the Supplemental Information.
Cell Isolation, Staining, and Flow Cytometry To obtain single-lung-cell suspensions, we perfused lungs with 10 mL of PBS through the right ventricle, cut them into small pieces, and digested them for 1 hr at 37 C in HBSS containing 1 mg/mL collagenase A (Roche) and 0.05 mg/mL DNase I (Roche). We then enriched single-cell suspensions in mononuclear cells by harvesting cells from the 1.080:1.038 g/mL interface with a density gradient (Easycoll from VWR). Cell phenotyping and sorting were performed on a FACSCANTO II and a FACSARIA III (BD Biosciences), respectively. Additional information can be found in the Supplemental Information.
Vascular Monocyte and Macrophage Depletion WT or Ccr2
À/À mice were injected intravenously with 200 mL of Clo-Lips or empty liposomes (PBS-Lips), and lung cells were harvested 24 hr later.
HDM-Induced Model of Asthma and CpG Treatments
Lightly isoflurane-anesthetized WT, Tlr9
, or ITIB mice were sensitized by two weekly i.n. instillations of vehicle (LPS-free saline) or HDM extracts (100 mg in 50 mL) on days 0 and 7. In experiments shown in Figure 3 , mice received i.n. installation of 50 mL saline containing 50 mg ODN or 50 mg CpG 7 days before the first HDM treatment (day À7) and were sacrificed at day 10. In experiments shown in Figure 4 , mice received i.n. installation of 50 mL saline containing 50 mg ODN or 50 mg CpG 7 days after the second HDM treatment (day 14). Mice were then challenged by an i.n. instillation of vehicle or HDM (100 mg in 50 mL) and were sacrificed at day 24. For adoptive-transfer experiments, WT mice were transferred intratracheally with 1.5 3 10 6 AMs or CpG IMs sorted from CpG-treated WT or Il10 À/À mice or with vehicle (50 mL saline) 24 hr before HDM administrations. We estimated AHR by assessing dynamic airway resistance in anesthetized animals with a FlexiVent small animal ventilator (SCIREQ). Mice were sacrificed, and BALF, lung, and LN cells were harvested and analyzed as described previously (Marichal et al., 2010) .
Additional details can be found in the Supplemental Information.
Additional Methods
Methodological details regarding cytologic examination, immunohistochemistry, microarrays, GSEAs, IL-10 detection, generation of mixed BM chimeras and parabiotic mice, EdU incorporation, ex vivo stimulation of tissue monocytes with CpG and LPS, western blot, real-time PCR, splenectomy, chemokine detection, and inhibition are described in the Supplemental Information.
Statistical Analyses
Statistical analyses were performed with R (version 3.2.4). Data from independent experiments were pooled for analysis in each data panel unless otherwise indicated. Raw data were transformed when needed and were back-transformed for graphical presentation. Assumptions of the normal distribution of residuals and homoscedasticity were verified with diagnostic plots. We considered a p value lower than 0.05 to be significant (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant).
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is Array Express: E-MTAB-5012. 
